Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. - Wikidata - awgldk - TriplyDB

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.

http://www.wikidata.org/entity/Q33236634

about

Lapatinib in the treatment of breast cancer Targeting HER2 in breast cancer: overview of long-term experience Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence?Risk factors for disease progression in HER2-positive breast cancer patients based on the location of metastases.Bioorthogonal two-component drug delivery in HER2(+) breast cancer mouse models.Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.Trastuzumab in the management of early and advanced stage breast cancer.Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu-pulsed dendritic cell vaccines.Breast cancer: beyond the cutting edge.Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.Novel targeted agents for the treatment of advanced breast cancer.Treatment beyond progression: is it moving from belief to evidence?Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.

P2860

Q28250382-0E41B482-16ED-47F7-9701-256C680AAAEA Q34272044-0F110E72-4828-456B-BAAE-27317CB2A1E6 Q35490056-D66718B0-480E-4ECB-A921-A36CC5912A00 Q35583942-82EAD9A1-87DA-475A-AD52-3C16597E3BED Q35584206-DD7D8A10-8779-452D-83C4-AA4E84811FDC Q35584899-3F8808A1-40D1-4E51-B898-CCF5D3F54598 Q36181895-E0AD367D-A2D5-4126-B19E-B4B0542E44F5 Q36789848-28119718-26F9-491B-9A26-41265A426B96 Q36955091-2E72AAFF-DE2A-4A75-A26A-4D28A160DF2B Q37236305-76E3BD7E-FBEA-4565-8662-87199E674A17 Q37290613-C107299E-A6CE-4434-BAF7-5125C67A3CAF Q37379081-AA354224-0E2F-4EBD-B873-DFDABCC24C66 Q37598890-50F98AAE-4BA9-41FC-B5D7-476029A04D08 Q37687375-3A62D5A9-84F3-4B8C-94CE-3C7EF388BED3 Q37725973-0F0005E5-49BC-47A0-B3ED-64B9B2FD9AE4 Q37970020-C9FA93BE-65A3-45D4-AAB7-1AE59420D076 Q38008723-37C01363-2E8C-4250-8666-31E6B96DA3B7 Q42995231-814B4024-C9C9-4F6B-B7E3-E2AA49779FB8 Q43502471-DF51A79B-07BE-4924-A9D1-EDCF7B00BC36 Q54368881-29C01F17-C3F7-48EC-8033-1059F0E35BAB

P2860

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.

http://www.wikidata.org/entity/Q33236634

description

2006 nî lūn-bûn

@nan

2006 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մարտին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Analysis of trastuzumab and ch ...... ation: an observational study.

@ast

Analysis of trastuzumab and ch ...... ation: an observational study.

@en

type

label

Analysis of trastuzumab and ch ...... ation: an observational study.

@ast

Analysis of trastuzumab and ch ...... ation: an observational study.

@en

prefLabel

Analysis of trastuzumab and ch ...... ation: an observational study.

@ast

Analysis of trastuzumab and ch ...... ation: an observational study.

@en

P1433

Q33236634-1DF03A8D-C3F5-48EC-992A-7644C4DB1700

P1476

Q33236634-8BECB9CD-3187-4546-932B-CC367D9D6C5A

P2093

Q33236634-0DB1DD49-806F-4A30-9163-1A37ACD4A48F

Q33236634-453DB14A-16EA-4265-9F1C-1B584A013AD2

Q33236634-50D2029F-80E5-4E99-8267-04A0ED1B17DB

Q33236634-7015EECF-E0E6-44D5-9170-B68244FE069D

Q33236634-70951883-9FB3-41C1-B915-9C4D8337B120

Q33236634-9317F8FD-5CE5-42BD-BF0B-450CE2B6C582

Q33236634-9A54BB8B-1E3A-4A19-BC90-74BE2ED6B982

Q33236634-AB180983-877E-4661-B9D2-981159A6A2F4

Q33236634-CFAAFDBC-B378-45CC-B2EC-8363C34166E3

Q33236634-F2804BB2-A9F4-4606-B9D1-680C675435E9

P2860

Q33236634-0480D5EC-10F2-45BC-9D4F-13BBC019FD0A

Q33236634-0954FBD7-6D47-4DD9-8A01-A699B107F390

Q33236634-13A435AC-F0A5-4630-A386-5BA8997CF104

Q33236634-14E63555-DCFF-4555-AD68-6C0D0E2F6BCB

Q33236634-3C1C2603-627A-40D6-8355-BBC5740AC0D9

Q33236634-3C21B0DB-B716-498A-9FB2-D5FE514AC7C3

Q33236634-416095FB-29FA-4073-AD4F-63B1D5D7F198

Q33236634-4604FA1A-AF01-4238-8E85-C8DB700FD4CD

Q33236634-4BC9B83A-8DCD-4C78-8A18-ADECD48E8254

Q33236634-540BFD62-D402-4A55-8741-2400AE9AD614

P2888

Q33236634-C2F6A86B-CB60-4B3B-820F-5251E0E45479

P304

Q33236634-60B1B5E6-5556-4594-B66D-5A193DBF46A8

P31

Q33236634-311687D1-8A6A-440C-9EC9-77D499A0CEC7

P356

Q33236634-9BC9532D-0C4C-4258-A352-3955D4831CBE

P407

Q33236634-A1826A2B-E0B9-4E90-8F6E-90D401CD8E2D

P478

Q33236634-51BF297A-5D87-4740-8FA5-929DAF5861B8

P50

Q33236634-030D6D7E-4E2A-4DC1-98DC-F15859333F9E

P577

Q33236634-38014A0D-69D9-42B5-A6D1-9D1CCE16B1B1

P5875

Q33236634-3A7A723C-9148-4D98-A30A-948ED8890A05

P6179

Q33236634-5D8AE9CE-B170-4642-85DD-B4EDFCD247E6

P698

Q33236634-BA99CAA6-DA62-48D2-9032-D1DE320DC735

P921

Q33236634-D254899E-4F11-482F-8D74-0EBB24859CEF

P932

Q33236634-20203176-497E-4A36-A6F4-6D94287CF80D

P356

P1433

P1476

Analysis of trastuzumab and ch ...... ation: an observational study.

@en

P2093

Catharina Wenzel

http://www.w3.org/2001/XMLSchema#string

Christoph C Zielinski

http://www.w3.org/2001/XMLSchema#string

Dagmar Hussian

http://www.w3.org/2001/XMLSchema#string

Gabriela Altorjai

http://www.w3.org/2001/XMLSchema#string

Gottfried J Locker

http://www.w3.org/2001/XMLSchema#string

Guenther G Steger

http://www.w3.org/2001/XMLSchema#string

Rupert Bartsch

http://www.w3.org/2001/XMLSchema#string

Ursula Pluschnig

http://www.w3.org/2001/XMLSchema#string

Ursula Sevelda

http://www.w3.org/2001/XMLSchema#string

Wolfgang Koestler

http://www.w3.org/2001/XMLSchema#string

P2860

Nonparametric Estimation from Incomplete Observations

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data.

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.

Combination of trastuzumab and vinorelbine in metastatic breast cancer.

A study of quality of life in cancer patients receiving palliative chemotherapy.

New combinations with Herceptin in metastatic breast cancer.

Trials of new combinations of Herceptin in metastatic breast cancer.

Trastuzumab/chemotherapy combinations in metastatic breast cancer.

Trastuzumab-based combinations in metastatic breast cancer: how to make a choice.

P2888

P304

63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-6-63

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Robert M. Mader

P577

2006-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7238390

http://www.w3.org/2001/XMLSchema#string

P6179

1011927773

http://www.w3.org/2001/XMLSchema#string

P698

16539726

http://www.w3.org/2001/XMLSchema#string

P921

P932

1431554

http://www.w3.org/2001/XMLSchema#string